Suggested remit: To appraise the clinical and cost effectiveness of sebetralstat within its marketing authorisation for treating acute attacks of hereditary angioedema.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6284

Provisional Schedule

Committee meeting 14 October 2025
Expected publication 17 December 2025

Project Team

Project lead Louise Jafferally

Email enquiries

Stakeholders

Companies sponsors KalVista (sebetralstat)
  Association for Respiratory Technology and Physiology
  Association of Genetic Nurses & Counsellors
  Association of Paediatric Emergency Medicine
  British Geriatrics Society
  British Paediatric Allergy, Immunity and Infection Group (BPAIIG)
  British Paediatric Respiratory Society
  British Skin Foundation
  British Society for Allergy & Clinical Immunology
  British Society for Genetic Medicine
  British Society for Haematology
  British Society for Immunology
  British Thoracic Society
  BSI Clinical Immunology Professional Network (BSI-CIPN)
  ILD-IN: Interstitial Lung Diseases Interdisciplinary Network
  Immunology and Allergy Nurses Group
  National Heart and Lung Institute
  Neonatal and Paediatric Pharmacists Group
  Primary Care Respiratory Society UK
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Paediatrics & Child Health
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Royal Society of Medicine - Allergy and Immunology Section
  UK Clinical Pharmacy Association
  UK Forum on Haemoglobin Disorders
Others The National Amyloidosis Centre
  Department of Health and Social Care
  NHS England
Patient carer groups Allergy UK
  Asthma and Lung UK
  Genetic Alliance UK
  HAE UK
  Immunodeficiency UK
  Jnetics
  NARA- The Breathing Charity
  South Asian Health Foundation
  Specialised Healthcare Alliance
  UK Primary Immune-deficiency Patient Support Charity (UKPIPS)
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Accord (icatibant)
  Celix Pharma (icatibant)
  Cipla (icatibant)
  CSL Behring (Berinert)
  Ethypharm (icatibant)
  Glenmark Pharmaceutical (icatibant)
  Martindale Pharmaceuticals (icatibant)
  Pharming Group N.V (ruconest)
  Piramal Critical Care (icatibant)
  Sandoz (icatibant)
  Takeda (cinryze, icatibant)
  Wockhardt (icatibant)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Hospital Information Services – Jehovah’s Witnesses
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  NHS Wales Joint Commissioning Committee
  Scottish Medicines Consortium
  Welsh Government
Relevant research groups Asthma, Allergy and Inflammation Research Trust
  British Association for Lung Research
  Cochrane Airways Group
  David Hide Asthma and Allergy Research Centre
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
14 March 2025 Invitation to participate
28 June 2024 - 26 July 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6284
28 June 2024 In progress. Scoping commenced.
28 April 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual